The extension brings total Series C financing to £18.8m with participation from US investor Modi Ventures.
"This investment reflects strong confidence in our technology, our team, and the impact Brainomix 360 Stroke and e-Lung can have on patient care. Stroke care depends on speed, while lung fibrosis care requires early identification and consistent clinical decision-making over time, underscoring the need for hospital technologies that support clinicians at the point of care. With this investment extension, we are well-positioned to enhance customer support across the US and Europe, accelerating the seamless integration of our technology into existing clinical workflows and expanding access to life-saving treatments."
Parkwalk led the Series B financing round to support the company in scaling its connectivity technology globally.
"From LEO satellite to terrestrial 5G deployments, the challenges of how to maximize the performance of the network, and in particular efficient use of energy and radio spectrum, are universal. Over the past few years, AccelerComm has continually demonstrated its position at the forefront of this technology, working with mobile operators, telecoms equipment vendors and the satellite industry to help supercharge communications. We’re thrilled to receive this backing from a range of industry-leading investors combined with the continued backing ongoing support of our existing shareholders and look forward to the company’s continued rapid growth and innovative development."
The Southampton developer has completed a Series A round led by Foresight Ventures following its recent product launch at CES.
"We would like to welcome our new investors to Audioscenic and would also like to say a huge thank you to our existing investors for their past and continued support"
AlbionVC led the investment round with participation from IP Group, Parkwalk, Hostplus, and Oxford Technology and Innovations EIS Fund.
"Citi Markets uses its deep software expertise to move faster and be more competitive. We find value in Diffblue’s auto-generation of test cases, which helps drive test consistency and coverage of our software. This frees up developers to focus on delivering higher quality software, faster – and improves our developers’ experience,"
The Oxford Science Enterprises-led round will support US expansion and continued domestic growth in healthcare.
"I’m delighted our investors have again demonstrated their belief in the vast potential that Navenio can bring by ensuring ‘right person, right place, right time’. Artificial intelligence is one of many technologies making a real-world impact in the health sector, and this investment enables the company to rapidly spearhead international digital transformation."
The Series B round was led by bp ventures with participation from a global investor syndicate.
"We are very excited about the amazing endorsement we have received from new and existing investors. This round of investment marks a key chapter in Oxbotica’s continued growth and pushes us forward in commercialising our autonomous software today, through key strategic go-to-market partnerships. The high-quality and global footprint of our investors cements our position as a leader in autonomy. We will use funds raised to accelerate the global deployment of our transformative technology."
